Who are Ifosfamide, Gemcitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bendamustine or gemcitabine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ifosfamide-gemcitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ifosfamide, Gemcitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ifosfamide, Gemcitabine (Ifosfamide, Gemcitabine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (alkylating agent + nucleoside analog). Area: Oncology.

phase 3 Chemotherapy combination (alkylating agent + nucleoside analog) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ifosfamide, Gemcitabine (Ifosfamide, Gemcitabine) — European Lung Cancer Working Party. This combination of ifosfamide and gemcitabine uses two chemotherapy agents that damage DNA and inhibit nucleotide synthesis to kill rapidly dividing cancer cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ifosfamide, Gemcitabine TARGET	Ifosfamide, Gemcitabine	European Lung Cancer Working Party	phase 3	Chemotherapy combination (alkylating agent + nucleoside analog)
Bendamustine or gemcitabine	Bendamustine or gemcitabine	Shanghai Junshi Bioscience Co., Ltd.	phase 3	Chemotherapy combination (alkylating agent + nucleoside analog)	DNA (bendamustine: alkylating agent; gemcitabine: ribonucleotide reductase inhibitor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (alkylating agent + nucleoside analog) class)

European Lung Cancer Working Party · 1 drug in this class
Shanghai Junshi Bioscience Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ifosfamide, Gemcitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/ifosfamide-gemcitabine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing